Primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder in children: A case report and review of the literature. Issue 9 (11th July 2022)

• Record Type: Journal Article
• Authors: Plumptre, Isabella R.; Said, Jordan T.; Sheu Song, Johanna; Corey, Kristen; LeBoeuf, Nicole R.
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-11
• Subjects: lymphoproliferative disorder -- PCSM‐TCLPD -- pediatric cutaneous oncology -- pediatric oncology -- peripheral T‐cell lymphoproliferative disorder -- primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29862
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Primary cutaneous CD4 + small/medium T‐cell lymphoproliferative disorder (PCSM‐TCLPD) is a rare benign lymphoproliferative disorder, recently redefined by the 2016 World Health Organization classification of lymphoid neoplasms. In adults, PCSM‐TCLPD responds well to monotherapy with surgical excision or local radiation, with or without topical/injected corticosteroids; in contrast, PCSM‐TCLPD has only rarely been reported in children, in whom treatments favored in adults may be non‐optimal. We present a 14‐year‐old male with PCSM‐TCLPD on the forehead, who achieved complete remission following biopsy, topical corticosteroids, and surgical excision. We also review all literature‐reported cases of pediatric PCSM‐TCLPD, emphasizing the disorder's benign nature and treatment responsiveness in children.